Press Releases

June 19, 2019 at 9:00 AM EDT

Summary Toggle Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration and License Agreement to Develop Additional Nucleic Acid Therapies for Rare Diseases

Scope of the collaboration expands to include up to 12 rare disease targets and includes Arcturus nucleic acid technologies to enable mRNA, DNA, and siRNA therapeutics $30 million of upfront payments to Arcturus, including $6 million cash for collaboration agreement amendment and a $24 million

PDF Version
June 13, 2019 at 7:00 AM EDT

Summary Toggle Arcturus Therapeutics Announces Redomiciliation to the United States as a Delaware Corporation

SAN DIEGO , June 13, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) (the “Company”), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that it has obtained approval

PDF Version
May 20, 2019 at 11:02 AM EDT

Summary Toggle Arcturus Therapeutics Presenting Data for ARCT-810 and the Arcturus mRNA + LUNAR® Technology Platform at the 2019 Annual Meeting of TIDES: Oligonucleotide and Peptide Therapeutics

SAN DIEGO , May 20, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT) (the “Company”), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that Pad Chivukula, Ph.D., Chief

PDF Version
May 13, 2019 at 7:00 AM EDT

Summary Toggle Arcturus Therapeutics Announces First Quarter Financial Results and Provides a Corporate Update

SAN DIEGO , May 13, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today reported its financial results for the quarter ended March 31, 2019

PDF Version
March 18, 2019 at 7:00 AM EDT

Summary Toggle Arcturus Therapeutics Provides Corporate Update and Reports Fourth Quarter and Year End 2018 Financial Results

SAN DIEGO , March 18, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics towards rare diseases, today reported its financial results for the quarter and year ended

PDF Version
February 11, 2019 at 7:05 AM EST

Summary Toggle Arcturus Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO , Feb. 11, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards rare, infectious, fibrotic, and respiratory diseases with significant unmet medical need, today announced

PDF Version
February 11, 2019 at 7:00 AM EST

Summary Toggle Arcturus Therapeutics Reassumes Full Worldwide Rights to ARCT-810, a Clinical Development Candidate for Ornithine Transcarbamylase (OTC) Deficiency

SAN DIEGO , Feb. 11, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the discovery, development and commercialization of therapeutics towards rare diseases, today announced that it will reassume 100% global rights for its flagship

PDF Version
January 3, 2019 at 7:00 AM EST

Summary Toggle Arcturus Therapeutics Appoints Andrew Sassine as Chief Financial Officer

SAN DIEGO , Jan. 03, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards rare, infectious, fibrotic, and respiratory diseases with significant unmet medical need, today announced

PDF Version
January 2, 2019 at 7:00 AM EST

Summary Toggle Arcturus Therapeutics to Develop ARCT-810 for Treatment of Ornithine Transcarbamylase (OTC) Deficiency

SAN DIEGO , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards rare, liver and respiratory diseases with significant unmet medical need, today announced the nomination

PDF Version
December 3, 2018 at 7:00 AM EST

Summary Toggle Arcturus Therapeutics to Host a Key Opinion Leader Call on Ornithine Transcarbamylase (OTC) Deficiency on December 11

SAN DIEGO , Dec. 03, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards rare, infectious, fibrotic, and respiratory diseases with significant unmet medical need, today announced

PDF Version